Skip to content

Prospective Analysis of Restorelle in the Treatment of Uterine Prolapse

Prospective Analysis of Restorelle in the Treatment of Uterine Prolapse

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02921451
Enrollment
40
Registered
2016-10-03
Start date
2016-08-31
Completion date
2020-08-31
Last updated
2019-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Prolapse

Brief summary

The purpose of this study is to determine the long term performance of Restorelle system for the treatment of uterine prolapse.

Detailed description

This study is being done to evaluate the performance of the Restorelle system, which uses Smartmesh - an ultra-lightweight mesh for uterine prolapse management. Most patients undergo a hysterectomy i.e. removal of the uterus when they have a prolapse. However, this has often been found to be an unnecessary operation. The investigators are studying the use of the Restorelle mesh system to preserve the uterus when there is a uterine prolapse.

Interventions

DEVICERestorelle Smartmesh

Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.

Sponsors

Coloplast A/S
CollaboratorINDUSTRY
Michigan Institution of Women's Health PC
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Subject is female. 2. Subject is at least 18 years of age. 3. Subjects who have already made the decision to proceed with uterine prolapse surgery using Restorelle Mesh. 4. Subject has uterine prolapse defined by Prolapse Quantification System Assessment (POPQ) score of C -2 or greater. 5. Subject reports a bothersome bulge they can see or feel per Pelvic Floor Distress Inventory Short Form 20 (PFDI-20) question 3, response of 2 or higher (i.e. response of somewhat, moderately or quite a bit). 6. Subject is willing to provide written informed consent. 7. Subject is willing and able to comply with follow-up regimen.

Exclusion criteria

1. Subject is pregnant or intends to become pregnant in the future. 2. Subject has a history of pelvic organ cancer (e.g. uterine, ovarian, bladder or cervical). 3. Subject has undergone any previous repair for pelvic organ prolapse. 4. Subject has undergone a hysterectomy. 5. Subject lacks competency of the English language.

Design outcomes

Primary

MeasureTime frameDescription
Number of patients who present with recurrence of uterine prolapse following surgery as assessed by failing to meet success criteriaWithin first two years after surgical procedureSuccess criteria will be defined through the examination of patient's Prolapse Quantification System Assessment (POPQ) score of C -1 or less and patient's report of bothersome bulge they can see or feel per Pelvic Floor Distress Inventory Short Form 20 (PFDI-20) question 3, response of 0 or 1 (i.e. response of not at all). Failure to meet this criteria will be considered recurrence of uterine prolapse.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026